

1 **Impact Of an Immune Modulator Mycobacterium-w On Adaptive Natural Killer Cells**
2 **and Protection Against COVID-19**

3 Sarita Rani Jaiswal^{1,2,5}, Jaganath Arunachalam¹, Ashraf Saifullah², Rohit Lakhchaura²,
4 Dhanir Tailor⁶, Anupama Mehta², Gitali Bhagawati³, Hemamalini Aiyer³, Bakulesh
5 Khamar⁴, Sanjay V. Malhotra⁶, Suparno Chakrabarti^{1,2*}
6 Cellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi¹,
7 Department of Blood and Marrow Transplantation² and Department of Pathology and
8 Microbiology, Dharamshila Narayana Super-speciality Hospital³, Research & Development,
9 Cadila Pharmaceuticals Ltd, Ahmedabad⁴, Amity Institute of Molecular Medicine and Stem
10 Cell Research, Amity University, Noida, Uttar Pradesh⁵, India, Department of Cell,
11 Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer
12 Institute, Oregon Health & Science University, Portland, OR, USA⁶.
13

14 **Running Title:** Mw for COVID-19
15

16 **Keywords:** *Mycobacterium w* (Mw), COVID-19, SARS-CoV-2, innate immunity, NKG2C,
17 Adaptive NK cells, NKG2A, ADCC
18

19 ***CORRESPONDENCE:**

20 Suparno Chakrabarti
21 Cellular Therapy and Immunology,
22 Manashi Chakrabarti Foundation, Vasundhara Enclave, New Delhi-110096, India
23 Email: foundationforcure@gmail.com
24

25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **ABSTRACT**

27 The kinetics of NKG2C⁺ adaptive natural killer (ANK) cells and NKG2A⁺inhibitory NK
28 (iNK) cells with respect to the incidence of SARS-CoV-2 infection were studied for 6 months
29 in a cohort of health-care workers following administration of heat killed *Mycobacterium w*
30 (Mw group) in comparison to a control group. In both groups, COVID-19 correlated with a
31 lower NKG2C⁺ANK cells at baseline. There was a significant upregulation of NKG2C
32 expression and IFN- γ release in Mw group ($p=0.0009$), particularly in those with lower
33 baseline NKG2C expression, along with downregulation of iNK cells ($p<0.0001$). This
34 translated to a significant reduction in incidence and severity of COVID-19 in the Mw group
35 (IRR-0.15, $p=0.0004$). RNA-seq analysis at 6 months showed an upregulation of ANK
36 pathway genes and an enhanced ANK mediated ADCC signature. Thus, Mw was observed to
37 have a salutary impact on the ANK cell profile and a long-term upregulation of ANK-ADCC
38 pathways, which could have provided protection against COVID-19 in a non-immune high-
39 risk population.

40

41

42

43

44

45

46

47

48

49

50

51 INTRODUCTION

52 The rapid explosion of the novel coronavirus, SARS-CoV-2, in early 2020, across the globe
53 overwhelmed even the most prepared health infrastructures[1] and exposed the healthcare
54 workers to an unforeseen situation, where they remained at the greatest risk of exposure to
55 the highest viral load, in the absence of a prevention or a cure. Despite a very high incidence
56 of infections, witnessed in the Indian population as well, there was a surprising sparing of the
57 urban slum-dwellers[2]. We hypothesized the role of a bolstered innate immune system
58 secondary to chronic pathogen exposure as a plausible reason for this phenomenon. We
59 reasoned that due to ubiquitous exposure to cytomegalovirus (CMV) in early childhood,
60 followed by exposure to a multitude of pathogens subsequently, there might be stronger
61 repertoire of NKG2C expressing adaptive natural killer (ANK) cells in this population [3].
62

63 Early CD56^{bright} NK cells have very high expression of NKG2A, which functions as an
64 inhibitory check-point in the process of functional maturation of NK cells[4]. Both NKG2C
65 and NKG2A bind to the same ligand, HLA-E, but the latter binds with several-fold greater
66 affinity compared to NKG2C [5]. Unlike somatic mutations witnessed in adaptive immune
67 cells to produce precise and clonal antigen specificity, NK cells express a plethora of
68 germline encoded activating and inhibitory receptors. The regulation of NK cell function,
69 which is termed as ‘licensing’, occurs with stochastic expression of killer-immunoglobulin-
70 like receptors (KIR), which bind to self- HLA-Class 1 antigens with biallelic specificity[6].
71 Expression of KIRs for which appropriate self-HLA antigens exist enable continued
72 inhibition of NK cells preventing autologous cytotoxicity. Hence, NKG2A⁺inhibitory NK
73 cells (iNK) are key to the prevention of autoreactivity of NK cells, prior to the KIR-driven
74 process of licensing. In a subset of mature and licensed NK cells, exposure to CMV leads to
75 the expression of a C-lectin type activating receptor, NKG2C, which is encoded by the

76 KLRC2 gene[7]. These cells are characterized by upregulation of NKG2C and
77 downregulation of the inhibitory counterpart, NKG2A[8]. This subset of NK cells, now
78 called NKG2C⁺ANK cells, exhibits the classic adaptive features, such as, clonal expansion,
79 persistence and recall memory more akin to memory cytotoxic T cells, than canonical NK
80 cells[9].

81

82 While the major subset of ANK cells express NKG2C, which is the defining phenotype,
83 several myeloid (FCεRG, PLZF) and B lymphoid (SYK, EAT-2) genes are downregulated,
84 and certain T lymphoid genes (CD3ζ, BCL11B) are upregulated in ANK cells[10]. The
85 alterations in these gene expressions in ANK cells favour an augmentation of antibody-
86 dependent cellular cytotoxicity (ADCC). In a small subset of ANK cells, the adaptive functions
87 might be demonstrable with epigenetic distribution of myeloid and lymphoid associated
88 genes as described above, even without upregulation of NKG2C expression[10; 11]. Hence,
89 for the sake of clarity, the ANK cells described in this study are NKG2C⁺ ANK cells.

90

91 In the context of haploidentical hematopoietic cell transplantation (HCT), NKG2C⁺ANK
92 cells were found to afford protection, not only against leukemia, but also a range of viral
93 infections, other than CMV. It was suggested that high NKG2C⁺ ANK cells was essential in
94 maintaining a non-inflammatory milieu without compromising anti-tumor effect post-
95 HCT[12; 13; 14; 15]. Based on these seminal findings along with the existing evidence that
96 certain natural infections, such as Hantavirus, as well as Influenza and BCG vaccinations are
97 capable of upregulating NKG2C⁺ANK cells in CMV-exposed populations[16; 17; 18], we
98 hypothesized that a novel heat killed *Mycobacterium w* (Mw), also known as *Mycobacterium*
99 *indicus pranii*, an approved immunomodulator in India [19], might upregulate NKG2C⁺ANK
100 cells and offer protection against SARS-CoV-2 (Severe Acute Respiratory Syndrome

101 Coronavirus-2) infections in the process. We studied the impact of Mw on the incidence of
102 COVID-19 (Corona Virus Disease 2019 caused by SARS-CoV-2) in a cohort-control study
103 in front line health care workers and its impact on the kinetics and repertoire of
104 NKG2C⁺ANK cells in the context of KLRC2 genotype.

105 MATERIALS AND METHODS

106 In a single-center non-randomised cohort control study, 50 HCWs from a single department
107 in the hospital were administered 0.1 ml *Mw* (Sepsivac, Cadila Pharmaceuticals, India)
108 intradermally in each arm on day 1 of the study (*Mw* group) and 50 randomly selected HCWs
109 from the rest of the institution were enrolled in a Control group. In addition, in the *Mw*
110 group, those without any local site reaction, who consented for second dose, were
111 administered an additional dose of 0.1 ml *Mw*, 30 days after the first dose. The observation
112 period of the study was 15 days after administration of the first dose of *Mw* to 180 days
113 (September 2020 to February 2021).

114 All HCW included in the study had nasopharyngeal swab evaluated for SARS-CoV-2 by
115 reverse transcriptase-polymerase chain reaction (RT-PCR), on development of symptoms
116 suggestive of COVID-19 or following contact with a patient, HCW or a family member in
117 contact with COVID-19 patient. Body temperature, pulse rate, oxygen saturation and self-
118 reporting of symptoms was evaluated before and after each working day[20]. COVID-19 was
119 diagnosed and its severity was graded as per established criteria. The duration of observation
120 was 6 months from September 2020 to February 2021. In addition, blood was collected, at
121 baseline, days 30, 60, and 100 from all the subjects, for evaluating the kinetics of
122 NKG2C⁺ANK cells and T cells. All subjects of this study also underwent evaluation for
123 CMV status (seropositive or seronegative).

124 All subjects provided written informed consent for participating in the study. The study was
125 approved by institutional ethics committee and registered with Clinical Trials Registry of
126 India (CTRI/2020/10/028326).

127 **Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) for Detection
128 of SARS-CoV-2**

129 All Covid tests were done by Truenat Real Time Reverse Transcriptase Polymerase chain
130 reaction (RT-PCR) test. Nasopharyngeal swabs were collected using standard nylon flocked
131 swab and inserted into the viral transport medium (VTM) provided from the same company
132 (Molbio diagnostics Pvt. Ltd. Goa, India). Samples were transported immediately to the
133 laboratory maintaining proper temperature and processed as per manufacturer's guidelines.
134 [Truenat Beta CoV Chip-based Real time PCR test for Beta Coronavirus, Molbio diagnostics
135 Pvt. Ltd. Goa, India]. The target sequence for this assay is E gene of Sarbeco virus and
136 human RNaseP (internal positive control). Confirmatory genes were RdRP gene and ORF1A
137 gene.

138 **Immunological monitoring**

139 Peripheral blood mononuclear cells (PBMC) were isolated from whole blood samples, by
140 density gradient centrifugations using HiSep™ LSM 1077 media. For surface staining, 0.5×10^6 cells were washed with phosphate-buffered saline (PBS) and stained with the following
141 antibodies which were used for phenotypic analysis: CD3(APC-H7, SK-7) CD16 (PE-Cy7,
142 B73.1), CD56 (APC R700, NCAM16.2), CD57 (BV605, NK-1), NKG2A (PE-Cy7, Z199),
143 CD4 (APC-H7), CD8 (Per-CP Cy), CD45RA (FITC), CD45RO (BV605), from BD
144 Biosciences, (San Jose, CA) and NKG2C (PE, REA205) from Miltenyi Biotec, Germany.
145 Cells were then incubated for 30 minutes. Viability was assessed with 7-AAD viability dye
146 (Beckman Coulter). For intracellular staining, cells were stained for IFN- gamma using
147 monoclonal antibodies for interferon-gamma (IFN- γ) (4S.B3) and perforin (Alexa647, DG9)

149 (BD Biosciences) after fixation and permeabilization with appropriate buffer (BD
150 Biosciences and e-biosciences, San Diego, CA, USA). Flow Cytometry was performed using
151 10 colour flow cytometry (BD FACS Lyrics) and the flow cytometry data was analyzed using
152 FlowJo software (v10.6.2, FlowJo). Unstained, single stained (one antibody/sample) as well
153 as fluorescence-minus-one (FMO) samples were used as controls for the acquisition as well
154 as the subsequent analysis. Statistical divergences were determined by the GraphPad Prism
155 software.

156 The gating strategy has been described earlier[15]. NKG2C⁺ANK cells were defined as
157 CD56^{dim}NKG2C⁺NKG2A⁻CD57⁺ subset of NK cells. NKG2C/NKG2A ratio was calculated
158 as relative % of NKG2C⁺NKG2A⁻ ANK cells / NKG2C⁻NKG2A⁺ iNK cells (Fig. S4).

159 **KLRC2 (NKG2C) genotyping**

160 KLRC2 gene encodes for NKG2C and is located in chromosome 12p13. For categorizing
161 subjects KLRC2 wildtype homozygous (*Wt*⁺/ *Wt*⁺), KLRC2 deletion homoygous (*Del*⁺/
162 *Del*⁺) and KLRC2 heterozygous (*Wt*⁺/ *Del*⁺), PCR-based KLRC2 genotyping was carried
163 out. DNA was isolated from the peripheral blood using QIAGEN QIAamp® DNA blood
164 mini kit method (Hilden, Germany). PCR amplification was carried out with forward and
165 reverse primer sequences as previously described[21]. PCR amplification was carried out in
166 20μl volume, containing 1x PCR master mix which has premixed taq polymerase, dNTPs,
167 PCR buffer (Thermo fisher scientific, Waltham, MA 02451, United States), 1.65 pmol
168 forward primers and reverse primers for KLRC2 deletion and wild type KLRC2 genes (see
169 Table S2), 100pg-1μg genomic DNA. Amplification was performed using a T100 thermal
170 cycler (Bio-Rad, Hercules, CA). Cycling temperature profiles were adopted from a previous
171 study[21] with minor modifications.

172 Briefly, the reaction mixture was subjected to one cycle of denaturation at 95°C for 10 min
173 followed immediately by 29 cycles of 95°C for 20 s, 50°C for 30 s, 72 °C for 40 s; and a final

174 extension at 72°C for 10 min before cooling to 4°C. A non-template control was included in
175 each batch of PCR reactions. PCR products were identified by running the entire PCR
176 product on a 2% agarose gel for 60 minutes at 70 Volts. The size of the amplicons was
177 determined by comparison against the migration of a 100-bp DNA ladder (GeneDireX, Inc,
178 Taoyuan County, Taiwan). Agarose gels were visualized and documented using the Gel doc
179 XR+ gel documentation system (Bio-Rad, Hercules, CA). An illustration of the PCR assay is
180 shown in supplementary figure (Fig. S5).

181 **RNA-seq Analysis**

182 This was carried out on both Mw and Control group at 6 months following exposure to Mw.
183 Four subjects from each group without COVID-19 were selected for the study.

184 **RNA isolation using Trizol method and polyA RNA selection:**

185 Peripheral blood mononuclear cells (PBMC) were isolated from whole blood samples by
186 density gradient centrifugations using HiSep™ LSM 1077 media (Himedia, Mumbai, India).
187 5 x 10⁶ PBMCs were used for RNA isolation using the Trizol method and followed by DNase
188 treatment for RNA purification. Purified RNA was quantified using a Qubit 4.0 fluorometer.
189 Take 5µg of total RNA used for the polyA RNA selection using NEB NEXT oligo d(T)₂₅
190 beads (NEB, MA, USA). PolyA RNA was quantified and integrity assessed using Qubit 4.0
191 fluorometer (Invitrogen, Waltham, Massachusetts, United States) according to manufacturer
192 instructions.

193 **cDNA library preparation and whole transcriptome sequencing using MinION 2.0-**
194 **Oxford Nanopore Technologies (ONT):**

195 For Direct cDNA Native Barcoding Sequencing (SQK-DCS109 with EXP-NBD104, oxford
196 nanopore technologies, Oxford, UK), 100ng of polyA RNA was used for the library
197 preparation. Using H minus Reverse Transcriptase (Invitrogen, Waltham, Massachusetts,

198 United States), complementary DNA (cDNA) was synthesised, followed by RNA
199 degradation and second-strand synthesis of cDNA. Double-stranded cDNA was used for the
200 end preparation, followed by native barcoding and adaptor ligation (all steps were followed,
201 according to the manufacturer's instructions). Ligated cDNA was loaded on the flow cell
202 (R9) in MinION Libraries were sequenced specifying 72 hours on the ONT MinION using
203 R9.4.1 flow cells and MinKNOW (v21.06.10, Microsoft Windows OS based) to generate
204 FAST5 files. FAST5 files were base-called with CPU based Guppy basecaller (v.5.0.11)
205 (ONT) to create summary text files and FASTQ files of the reads for further downstream
206 analysis.

207 **Sample pre-processing and Quality assessment:**

208 Demultiplexing of the pooled samples and adapter removal was carried out using inbuilt
209 algorithm of Minknow. Linux Long Time Support (v.20.04) Operating System was used for
210 all the analysis. A comprehensive report of the sequencing was generated by NanoComp
211 (<https://github.com/NanoComp/h5utils>) tool and sequencing quality assessment was done by
212 FastQc tool (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Sample reads
213 were subjected to a minimum phred quality score of 9 and reads with lower quality were
214 filtered out using NanoFilt (<https://github.com/wdecoster/nanofilt>) tool. Some initial reads are
215 usually prone to low base-calling quality. Hence, 50bp of each initial reads from every
216 sample were filtered out for quality maintenance using NanoFilt tool only. All the samples
217 were subjected to quality assessment before and after quality filtering.

218 **Differential Gene Expression analysis:**

219 Differential Gene Expression analysis (DGE) was done using “pipeline-transcriptome-de”
220 (<https://github.com/nanoporetech/pipeline-transcriptome-de>) pipeline. This pipeline from
221 nanopore tech uses snakemake, minimap2, salmon, edgeR, DEXSeq and stageR to automate

222 DGE workflows on long read data. Pipeline was set to make only reads aligned to minimum
223 3 samples to be considered for analysis. A separate conda (<https://docs.conda.io/en/latest/#>)
224 environment was created on Linux OS to host this pipeline. Quantification and DGE was
225 done by R language based (<https://www.r-project.org/>) tool edgeR
226 (<https://bioconductor.org/packages/release/bioc/html/edgeR.html>) employing gene-wise
227 negative binomial regression model and normalisation factor (Transcript Mean of M-value)
228 for each sequence library. Differentially expressed genes (DEGs) with log2Fold Change
229 ($\log_2\text{Fc} \geq 0.5, \leq -0.5$ and associated p-value < 0.05) were selected as significant for further
230 analysis. Annotation of DEGs was fetched from ENSEMBL database
231 (<https://asia.ensembl.org/index.html>) using R language biomaRt package
232 (<https://bioconductor.org/packages/release/bioc/html/biomaRt.html>). All the file compilation
233 was ultimately done using Microsoft Excel and Libre Office calc.

234 Hierarchical clustering analyses was performed between all four samples of each group to
235 generate Heatmap from normalised log2 counts per million expression values using web-
236 based START(Shiny Transcriptome Analysis Resource Tool,
237 <https://kcv1.shinyapps.io/START/>) tool. Comparative gene expression boxplot on the basis of
238 log2 Counts per million between Mw and Control group were generated from START tool.
239 Volcano plot involving all DEGs were created using R language based ggplot2
240 (<https://ggplot2.tidyverse.org/>) package.

241 **Gene Ontology (GO) Pathway Analysis:**
242 Pathway enrichment analysis was done for significant DEGs using g:Profiler
243 (<https://biit.cs.ut.ee/gprofiler/gost>) using Gene Ontology. Pathways related to adaptive
244 Natural killer (ANK), ADCC and innate immune inflammatory pathways were considered for
245 focussed analysis. Functional enrichment was done by R based clusterProfiler (v. 4.2.1)

246 <https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html> tool. An adjusted p-
247 value threshold of ≤ 0.05 was considered for this study.

248 **Statistics**

249 Lymphocyte subsets have been represented as % of the parent population. Binary variables
250 were compared between the groups using chi square test. The continuous variables were
251 analysed using independent sample t-test considering Levene's test for equality of variances
252 and non-parametric tests (Mann-Whitney U test). P value < 0.05 was considered to be
253 significant. GraphPad Prism (version 8.0 for Windows, GraphPad Software, La Jolla, CA,
254 USA) was used for the statistical assessment (unpaired low-parametric Mann-Whitney or
255 Kruskal-Wallis test and Spearman correlation). Recursive partitioning analysis was carried
256 out using *rpart* package (<https://cran.r-project.org/web/packages/rpart/index.html>) in R
257 (<https://cran.r-project.org/>) to generate optimal cut off for ANK cells at baseline.
258 The efficacy of Mw in reducing the incidence of COVID-19 was calculated in terms of attack
259 rates incidence risk ratio (IRR), absolute risk reduction (ARR) and intervention efficacy (see
260 Table S3). This was calculated in terms of infections occurring at 2 weeks after
261 administration of Mw is customary in prophylactic studies as well as those occurring any
262 time between during the study period.

263

264

265

266

267

268

269

270

271

272

273

274 **RESULTS**

275 **Mw and COVID-19**

276 The characteristics and outcomes of the Mw and control groups are detailed in Table 1.

277 All subjects were seropositive for CMV.

278 Twenty (3 in Mw group vs 17 in the control group) out of 100 subjects in the entire cohort
279 had symptomatic COVID-19 during the study period (15 days-6 months). All infections on
280 the Mw group were mild, while 6 of 17 in control group had moderate disease and required
281 hospital admission ($p=0.01$). No deaths were recorded in either group. In Mw group all three
282 infections occurred beyond 150 days. In the control group, 17 subjects had COVID-19 at a
283 median of 56 days (range, 18–135). Additionally, three mild symptomatic COVID-19 were
284 documented within the first 7 days of Mw administration. The incidence rates (IR) of
285 COVID-19 were 3.57 and 24.05 /10,000 person-days in Mw and control groups respectively
286 (IRR-0.15, 95% CI, 0.04-0.5, $p=0.0004$) with an efficacy rate for Mw being 82.35%, (95%
287 CI, 50-96 %) (Fig. 1).

288 Twenty-four subjects in the Mw group were randomised 1:1 to receive the second dose, 30
289 days after the first dose. Impact of the second dose on protection could not be analysed as
290 none of the randomised subjects developed COVID-19 during the study period.

291

292 **Safety Profile of Mw**

293 Mw was safe with no systemic adverse effects. Only one subject had mild fever (37.5°C) for
294 less than two hours, 24 hours after administration, which was self-limiting. However, 14%
295 had pain at the local sites, with 12% developing pain and erythema lasting for more than 72

296 hours. In 8% of the subjects, ulceration was noted at the local site with long-term scars
297 similar to that observed with BCG vaccination. Those with severe local reactions were all
298 older (35 years and above), compared to the median age of the group (28 years).

299 **Baseline NKG2C⁺ANK cells correlated with increased risk of COVID-19 in both Mw
300 and Control groups**

301 Baseline data on immune parameters was available in 80 subjects in the overall cohort, 30 in
302 control and 50 in Mw group. The NKG2C⁺ANK cells in those who got infected (n=16) was
303 7.9 ± 6.1 , (includes 3 who got infected within 7 days of receiving Mw) compared to $20.9 \pm$
304 13.8 in those who remained uninfected ($p= 0.0005$).

305 Amongst the 30 subjects in the control group, who were tested at baseline for NKG2C⁺ANK
306 cells, 10 developed COVID-19. The NKG2C⁺ANK cells at baseline was 9.7 ± 6.6 in those
307 with infection compared to 17.7 ± 5.56 in those without infection ($p=0.0016$). Those who
308 acquired the infection in the Mw group, also had a lower baseline NKG2C⁺ANK (4.76 ± 3.9
309 vs 22.3 ± 16.1 , Fig. 5, $p=0.01$). Interestingly, 2 of the 3 subjects, experiencing COVID-19 in
310 the Mw group, did not show any increment in NKG2C⁺ANK levels or NKG2C/NKG2A
311 ratios at any of the time-points. We did not find any correlation between expression of
312 NKG2A as well as NKG2C/NKG2A ratio with development of symptomatic COVID-19 in
313 this study.

314 **Mw and ANK cells**

315 Thirty subjects from the Mw group and 15 from the control group, who did not develop
316 COVID-19 or any other significant infection during the study period were included in the
317 final longitudinal analysis of immunological impact of Mw.

318 **Baseline ANK levels did not differ, but ANK Kinetics at 60 days were different in the
319 Mw group**

320 There was no difference in overall NK cells between the two groups at baseline or at
321 subsequent time-points. NKG2C⁺ANK and NKG2A⁺ iNK cells expression were also similar
322 at baseline in both groups (Fig. 2, A & B). The data from control group shown in further
323 comparisons only pertain to the baseline and day 60, as the values in the control group for
324 both NKG2C⁺ ANK cells and NKG2A⁺ iNK cells did not change significantly at any of the
325 time-points.

326 In the Mw group on the other hand, (Fig. 2, A- D), NKG2C⁺ANK cells increased from
327 baseline (23.0 ± 22.9) to peak at day 60 (40.9 ± 16.5 , day 60 $p=0.0009$, Fig. 2 C), while
328 NKG2A⁺ iNK cells reduced from 36.23 ± 14.4 to 26.22 ± 14.04 on day 30 and 6.17 ± 6.01 on
329 day 60 ($p<0.0001$, Fig. 2 D). The absolute values as well as the log two-fold change (log2FC)
330 were significantly different for both NKG2C⁺ANK cells (1.5 ± 1.9 vs -0.62 ± 0.89 , $p=0.0002$,
331 Fig. 2 E) as well as NKG2A⁺ iNK cells (-2.9 ± 1.2 vs 0.17 ± 0.29 , $p<0.0001$, Fig. 2 E) cells at
332 day 60, compared to the control group.

333 **The impact of Mw on NKG2C upregulation was only observed in those with low ANK
334 cells at baseline**

335 A cut-off of 15% was established for NKG2C⁺ANK cells based on recursive partitioning for
336 evaluating effect of base line value on NKG2C upregulation. Upregulation of NKG2C⁺ ANK
337 cells was seen in those with NKG2C⁺ ANK levels below 15% (Low ANK group). From a
338 baseline value of 4.7 ± 2.2 , this increased to 8.9 ± 4.9 on day 30 ($p=0.005$,) and 43.3 ± 19.12
339 on day 60 ($p<0.0001$, Fig. 3 A). This was also reflected in the log2FC values.

340 In those with NKG2C⁺ANK levels above 15% (High NKG2C⁺ANK), there was no
341 significant change in absolute values of NKG2C⁺ANK cells at either day 30 or day 60(Fig. 3
342 B), but a positive impact on log2FC was noted ($p=0.04$, Fig. 3 E).

343 **The impact on NKG2A⁺iNK downregulation was irrespective of baseline NKG2C⁺ANK
344 expression**

345 The downregulation of NKG2A⁺iNK cells was noted in the Mw group, irrespective of
346 baseline NKG2C expression [Fig. 3, C & D]. The downregulation of NKG2A⁺iNK cells was
347 significant at day 60 in the Mw group, irrespective of baseline NKG2C expression (-2.99 ±
348 1.21 vs 0.23 ± 0.23, p<0.0001 for Low ANK group and -2.84 ± 1.28 vs 0.09 ± 0.35, p<0.0001
349 for High ANK group) [Fig. 3 F].

350 **Mw had a sustained effect on NKG2C+ANK/ NKG2A+iNK ratio until 100 days**

351 NKG2C⁺ ANK/NKG2A⁺ iNK ratio was similar between two groups at baseline. However,
352 this increased in the Mw group at day 60 (12.3 ± 9.2, p<0.0001) and persisted until day 100
353 (7.44 ± 13.55, p=0.01). This was witnessed for both Low and High ANK group in the Mw
354 cohort but not in the control cohort. [Fig. 4, A- D].

355 **IFN-γ release was higher in Mw group at 60 days**

356 IFN-γ release potential of the NKG2C⁺ANK cells was studied at baseline and at 60 days.
357 This was similar between the groups at the baseline (mean-6.7 vs 6.4). However, this was
358 significantly increased in the Mw group at day 60, compared to the control group (mean-
359 27.96 vs 9.9, p=0.01, Fig. 4 E).

360

361 **KLRC2 and kinetics of ANK cells**

362 KLRC2 deletion was studied in the Mw group only. KLRC2 Wt^{+/del⁺} was detected in 36%
363 of the subjects in the Mw group. This was not associated with any significant decrease in the
364 baseline NKG2C⁺ANK levels (15.1 ± 17.67 vs 20.4 ± 17.96, p=0.46). There was no
365 difference in the effect of Mw between the KLRC2 Wt^{+/Wt⁺} and Wt^{+/Del⁺} groups at day 60
366 either (p=0.26), although the log2FC increase tended to be higher in the Wt^{+/Del⁺} group

367 (p=0.12) [Fig. S1, A & B]. KLRC2 deletion was detected in 2 out of 6 with COVID-19,
368 compared to 16 out of 44 without COVID-19 (p=0.6).

369 **Mw did not influence kinetics of naïve and memory T cell subsets**

370 CD4 and CD8 cells remained unchanged, as were the CD45RA and CD45RO subsets at days
371 30 and 60 in the Mw group [Fig. S2, A & B]. The same was witnessed in the control group
372 (data not shown).

373 NKG2A expression on CD3⁺ T cells was examined at baseline and subsequent timelines.
374 Despite a significant downregulation of NKG2A observed in NK cells, no such effect was
375 evident in the T cells. [Fig. S2 C]

376 **Impact of the second dose of Mw on NKG2C⁺ANK cells**

377 There was no difference between in NKG2C⁺ANK cells at day 60 and day 100 (p=0.28) in
378 double vs single doses of Mw (Fig. 6 A). However, NKG2A⁺ iNK cell expression was
379 significantly reduced at day 100 (7.7 ± 16.77 vs 24.85 ± 19.43 , p=0.04) in double dose group
380 (Fig. 6 B). The NKG2C/NKG2A ratio was also significantly higher in double dose group at
381 day 100 (10.42 ± 7.19 vs 2.08 ± 3.26 , p <0.001) [Fig. 6 C]. There was no difference in CD4⁺
382 & CD8⁺ T cells and memory or naïve subsets at day 60 and 100 between the randomized
383 groups (data not shown).

384 **RNAseq Analysis at 6 months**

385 Sequencing and mapping metrics along with Quality scores are shown in Supplement 1
386 (Table S1)

387 **Identification of differentially expressed genes**

388 Based on criteria of p-value < 0.05, a total of 3,603 out of 16,058 were found to be
389 differentially expressed genes (DEGs) between Mw and Control group, including 1568 genes
390 that were upregulated and 2035 genes that were downregulated in Mw group. Those DEGs
391 with a log2 fold change of at least 0.5 were considered for further analysis. DEGs related to

392 Adaptive Natural Killer Cells and ADCC were selected out to analyse the differential
393 expression pattern between two groups.

394 **ANK and ADCC genes were upregulated in Mw group**

395 Nineteen DEGs were associated with ANK and ADCC pathways (Fig. 7, A & B). 11 genes
396 were upregulated and 8 were found to be downregulated in Mw group. KLRC2 (NKG2C),
397 BCL11B, ARID5B, B3GAT1 (CD57), KLRC4 were upregulated and KLRC1(NKG2A),
398 ZBTB16 (PLZF1), KIT and SH2D1B (EAT-2) were downregulated in relation to ANK
399 pathway (Fig. 7 C). In the ADCC pathway, CD247 (CD3ζ), FCGR1A (CD64),
400 FCGR2A(CD32a), FCGR2C (CD32c) were upregulated and FCER1G was downregulated
401 (Fig. 7 C), favouring ANK mediated ADCC.

402 **Gene Ontology (GO) Pathway Analysis**

403 Functional enrichment of differentially expressed genes were carried out on the selected
404 genes focusing on ANK and ADCC pathways. Selected 19 DEGs were analysed using
405 goProfiler and clusterProfiler for Gene Ontology (GO). GO analysis of the selected DEGs
406 demonstrated that immune response-regulating cell surface receptor signalling pathway
407 (GO:0002768) and positive regulation of natural killer cells mediated toxicity (GO:0045954)
408 were significantly upregulated (Fig. 7 D).

409

410 **DISCUSSION**

411 The identification of NK cells with ability to persist and mount recall responses has
412 challenged the traditional compartmentalization of adaptive and immune responses[22; 23].
413 The NKG2C⁺ANK cells explored in this study are known to be induced by primary exposure
414 to CMV[24; 25]. However, in CMV exposed patients, these NKG2C⁺ANK cells have been
415 found to proliferate in response to a variety of viral pathogens, including HIV, HCV,
416 Hantavirus, influenza, and pox viruses[16; 26; 27; 28; 29]. The unique nature of this non-

417 antigen specific recall response against a wide variety of pathogens, puts NKG2C⁺ANK cells
418 at the forefront in the battle against novel pathogens such as SARS-CoV-2 [3; 30; 31; 32; 33;
419 34], where antigen-specific adaptive response generated from T and B cells are absent at the
420 outset of the pandemic.

421 BCG vaccine has been shown to induce long-term heterologous memory response of NK
422 cells[31]. This has been studied, both in the context of infections as well as cancer[35].

423 Influenza vaccination has been shown to induce proliferation of NKG2C⁺ANK cells with
424 potential for enhanced cytokine release[36]. These considerations prompted us to explore this
425 novel immunomodulator, Mw, which has been extensively studied as adjuvant or prophylaxis
426 in other infections[19; 37; 38], and some forms of cancers including BCG resistant bladder
427 cancer [39].

428 Our study demonstrated that prophylaxis with Mw was associated with a six-fold reduction in
429 the incidence of symptomatic COVID-19 in this high-risk cohort over a 6-month period. This
430 protective efficacy was accompanied by a sharp increase in NKG2C⁺ANK cells between 30-
431 and 60-days following exposure to Mw. A critical observation was a steep decline in the
432 expression of the inhibitory counterpart, NKG2A⁺iNK cells, which continued through 100
433 days. This resulted in an increasing NKG2C/NKG2A ratio through the study period.

434 Exposure to a second dose of Mw resulted in a continued downregulation of NKG2A⁺ iNK
435 cell and a further increase in NKG2C/NKG2A ratios. The importance of the relative
436 proportion of NKG2C and NKG2A expressing NK cells could be appreciated better in the
437 context of the fact that the inhibitory impact of NKG2A overrides that of NKG2C, as it binds
438 to the ligand HLA-E with several fold greater affinity than NKG2C[5]. In the context of
439 SARS-CoV-2 infection, in-vitro studies have demonstrated that the viral spike protein-1 (SP-
440 1) upregulates NKG2A on NK cells and HLA-E on the infected lung epithelial cells, causing
441 a strong inhibition of cytotoxicity of NK cells[40]. Our group has demonstrated a correlation

442 between high expression of NKG2A, suppression of NKG2C, and adverse outcome following
443 severe COVID-19 lung disease, despite viral clearance[34]. It is possible that the adverse
444 effect of KLRC2 deletion genotype as reported earlier[30], was mitigated by Mw. Hence, it
445 might be inferred that if any intervention can achieve the reverse, i.e., downregulation of
446 NKG2A and upregulation of NKG2C expression, this might offer innate protection against
447 COVID-19.

448

449 In our study, a lower baseline NKG2C⁺ANK cells predisposed to COVID-19 in the control
450 group. The same in the Mw group was associated with COVID-19 in the first 2 weeks, but
451 not thereafter until 150 days. It is also worth noting that COVID-19 occurring in the Mw
452 group beyond 150 days was associated with failure in modulation of the adverse
453 NKG2C⁺ANK cell profile in 2 out of 3 subjects. Apart from phenotypic alteration, Mw
454 seemed to influence the cytokine release potential as well, as evidenced by an increase in
455 IFN- γ release at day 60 in the Mw group, compared to both baseline as well as the control
456 group. Furthermore, upregulation of NKG2C was dominantly noted in those with a lower
457 baseline NKG2C⁺ANK cell. Upregulation of NKG2C expression might be more tightly
458 controlled, unlike downregulation of NKG2A, in mature and licensed NK cells, where an
459 inhibitory regulation mediated by NKG2A is physiologically redundant due to KIR-mediated
460 inhibitory control. More importantly, this also demonstrates that downregulation of
461 checkpoint receptor NKG2A is an important determinant of a favorable ANK profile.

462

463 RNA-seq analysis confirmed that upregulation of ANK pathway was evident at 6 months in
464 the Mw group. Apart from upregulation of KLRC2 and B3GAT1 and downregulation of
465 KLRC1, the key transcription factor in the ANK pathway, BCL11b, was persistently
466 upregulated[41]. Downregulation of EAT-2 and PLZF further corroborated the classic gene

467 expression signature of ANK cells. Moreover, increased expression of AT-rich interaction
468 domain 5B (ARID5B), as demonstrated in the Mw group plays an important role in enhanced
469 metabolism in ANK cells as well as increased IFN- γ release and survival[42]. DGE analysis
470 also revealed an enhancement of ANK mediated ADCC pathway, with significant
471 upregulation of CD247 along with downregulation of FCER1G, which is a typical signature
472 of ANK-ADCC[43]. Both CD247 and FCER1G are adapter molecules for FCGRIIIA (CD16)
473 with CD247 possessing 3 ITAMs against one ITAM of FCER1G, increasing the ADCC
474 several folds[44]. It is possible that Mw induced augmentation of NK-ADCC might
475 potentiate the efficacy of SARS-CoV2 vaccines as well[45]. Prior studies on Mw have
476 explored its effect on TLRs via the monocyte/macrophage pathway[46; 47; 48] and not on
477 NK cells. The suggested mechanistic pathway as to how Mw might be favorably influencing
478 ANK mediated protection against COVID-19 has been depicted in Fig. 8.

479

480 In conclusion, our study shows that Mw offered protection against COVID-19 in a high-risk
481 population at the peak of the pandemic in the absence of antigen-specific immunity. This
482 could be through a sustained upregulation of NKG2C $^+$ ANK cell and ADCC pathway, along
483 with simultaneous downregulation of NKG2A $^+$ iNK pathways. If borne out in a randomized
484 setting, these findings might usher a novel approach to bolster heterologous immunity in the
485 current and future pandemics and identify ANK pathway in the immunological vulnerability
486 for developing COVID-19.

487

488

489

490

491

492 **Acknowledgement:** We thank all the nursing and technical staff of the department who have
493 assisted in carrying out this study. This study was supported by a grant from Indo-US Science
494 and Technology Forum (IUSSTF/VN-COVID/049/2020).

495 **Authorship Contribution:** SRJ, BK and SC designed the study. AM, RL, GB and HM
496 performed the study. SRJ, AS, AM, GB and HM collected the data. SRJ, AS, JA, SVM, DT
497 and SC analyzed the data; SRJ and SC wrote the manuscript. All the co-authors reviewed and
498 approved the manuscript.

499 **Conflicts of Interest Statement:** BK and SVM are employed by Cadila Pharmaceuticals
500 Ltd. The remaining authors declare that the research was conducted in the absence of any
501 commercial or financial relationships that could be construed as a potential conflict of
502 interest.

503 **Funding:** This study was supported by grant from Indo-US Science and Technology Forum
504 (IUSSTF/VN-COVID/049/2020).

505 **Data Availability Statement:** The RNA-seq data generated from the experiment related to
506 study have been uploaded in ‘Sequence Read Archive’ (SRA)

507

508

509

510

511

512

513

514

515

516

517

518 **REFERENCE**

- 519 [1] D. Blumenthal, E.J. Fowler, M. Abrams, and S.R. Collins, Covid-19 - Implications for the
520 Health Care System. *N Engl J Med* 383 (2020) 1483-1488.
- 521 [2] J. Kaushal, and P. Mahajan, Asia's largest urban slum-Dharavi: A global model for
522 management of COVID-19. *Cities* 111 (2021) 103097.
- 523 [3] S.R. Jaiswal, P. Malhotra, D.K. Mitra, and S. Chakrabarti, Focusing On A Unique Innate
524 Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19:
525 Harnessing The Ubiquity Of Cytomegalovirus Exposure. *Mediterr J Hematol Infect*
526 *Dis* 12 (2020) e2020047.
- 527 [4] L. Moretta, F. Locatelli, D. Pende, S. Sivori, M. Falco, C. Bottino, M.C. Mingari, and A.
528 Moretta, Human NK receptors: from the molecules to the therapy of high risk
529 leukemias. *FEBS Lett* 585 (2011) 1563-7.
- 530 [5] V. Beziat, B. Hervier, A. Achour, D. Boutolleau, A. Marfain-Koka, and V. Vieillard,
531 Human NKG2A overrides NKG2C effector functions to prevent autoreactivity of NK
532 cells. *Blood* 117 (2011) 4394-6.
- 533 [6] V. Beziat, B. Descours, C. Parizot, P. Debre, and V. Vieillard, NK cell terminal
534 differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.
535 *PLoS. One* 5 (2010) e11966.
- 536 [7] S. Lopez-Verges, J.M. Milush, B.S. Schwartz, M.J. Pando, J. Jarjoura, V.A. York, J.P.
537 Houchins, S. Miller, S.M. Kang, P.J. Norris, D.F. Nixon, and L.L. Lanier, Expansion
538 of a unique CD57(+)NKG2Chi natural killer cell subset during acute human
539 cytomegalovirus infection. *Proc Natl Acad Sci U S A* 108 (2011) 14725-32.
- 540 [8] M. Della Chiesa, S. Sivori, S. Carlomagno, L. Moretta, and A. Moretta, Activating KIRs
541 and NKG2C in Viral Infections: Toward NK Cell Memory? *Front Immunol* 6 (2015)
542 573.
- 543 [9] J.C. Sun, and L.L. Lanier, Natural killer cells remember: an evolutionary bridge between
544 innate and adaptive immunity? *Eur J Immunol* 39 (2009) 2059-64.
- 545 [10] H. Schlums, F. Cichocki, B. Tesi, J. Theorell, V. Beziat, T.D. Holmes, H. Han, S.C.
546 Chiang, B. Foley, K. Mattsson, S. Larsson, M. Schaffer, K.J. Malmberg, H.G.
547 Ljunggren, J.S. Miller, and Y.T. Bryceson, Cytomegalovirus infection drives adaptive
548 epigenetic diversification of NK cells with altered signaling and effector function.
549 *Immunity* 42 (2015) 443-56.
- 550 [11] L. Muccio, M. Falco, A. Bertaina, F. Locatelli, F. Frassoni, S. Sivori, L. Moretta, A.
551 Moretta, and M. Della Chiesa, Late Development of FcepsilonRgamma(neg)
552 Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in
553 Umbilical Cord Blood Transplantation Recipients. *Front Immunol* 9 (2018) 1050.
- 554 [12] S.R. Jaiswal, P. Bhakuni, G. Bhagawati, H.M. Aiyer, M. Soni, N. Sharma, R.R. Jaiswal,
555 A. Chakrabarti, and S. Chakrabarti, CTLA4Ig-primed donor lymphocyte infusions
556 following haploidentical transplantation improve outcome with a distinct pattern of
557 early immune reconstitution as compared to conventional donor lymphocyte infusions
558 in advanced hematological malignancies. *Bone Marrow Transplant* (2020).

- 559 [13] S.R. Jaiswal, P. Bhakuni, G. Bhagwati, H.M. Aiyar, A. Chakrabarti, and S. Chakrabarti,
560 Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following
561 Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is
562 Associated With Increased Chronic Graft-Versus-Host Disease. *Transplantation* 104
563 (2020) e23-e30.
- 564 [14] S.R. Jaiswal, and S. Chakrabarti, Natural killer cell-based immunotherapy with
565 CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.
566 *Immunotherapy* 11 (2019) 1221-1230.
- 567 [15] S.R. Jaiswal, S. Chakraborty, R. Lakhchaura, P. Shashi, A. Mehta, M. Soni, and S.
568 Chakrabarti, Early and Sustained Expansion of Adaptive Natural Killer Cells
569 Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte
570 Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
571 *Transplantation and Cellular Therapy* 27 (2021) 144-151.
- 572 [16] N.K. Bjorkstrom, T. Lindgren, M. Stoltz, C. Fauriat, M. Braun, M. Evander, J.
573 Michaelsson, K.J. Malmberg, J. Klingstrom, C. Ahlm, and H.G. Ljunggren, Rapid
574 expansion and long-term persistence of elevated NK cell numbers in humans infected
575 with hantavirus. *J Exp Med* 208 (2011) 13-21.
- 576 [17] J.C. Sun, and L.L. Lanier, Is There Natural Killer Cell Memory and Can It Be Harnessed
577 by Vaccination? NK Cell Memory and Immunization Strategies against Infectious
578 Diseases and Cancer. *Cold Spring Harb Perspect Biol* 10 (2018).
- 579 [18] F. Abebe, Immunological basis of early clearance of *Mycobacterium tuberculosis*
580 infection: the role of natural killer cells. *Clin Exp Immunol* 204 (2021) 32-40.
- 581 [19] I.S. Sehgal, R. Agarwal, A.N. Aggarwal, and S.K. Jindal, A randomized trial of
582 *Mycobacterium w* in severe sepsis. *J Crit Care* 30 (2015) 85-9.
- 583 [20] Z. Wu, and J.M. McGoogan, Characteristics of and Important Lessons From the
584 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
585 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*
586 (2020).
- 587 [21] R. Miyashita, N. Tsuchiya, K. Hikami, K. Kuroki, T. Fukazawa, M. Bijl, C.G.
588 Kallenberg, H. Hashimoto, T. Yabe, and K. Tokunaga, Molecular genetic analyses of
589 human NKG2C (KLRC2) gene deletion. *Int Immunol* 16 (2004) 163-8.
- 590 [22] J.G. O'Leary, M. Goodarzi, D.L. Drayton, and U.H. von Andrian, T cell- and B cell-
591 independent adaptive immunity mediated by natural killer cells. *Nat Immunol* 7
592 (2006) 507-16.
- 593 [23] L.L. Lanier, Shades of grey — the blurring view of innate and adaptive immunity.
594 *Nature Reviews Immunology* 13 (2013) 73-74.
- 595 [24] F. Cichocki, S. Cooley, Z. Davis, T.E. DeFor, H. Schlums, B. Zhang, C.G. Brunstein,
596 B.R. Blazar, J. Wagner, D.J. Diamond, M.R. Verneris, Y.T. Bryceson, D.J. Weisdorf,
597 and J.S. Miller, CD56dimCD57+NKG2C+ NK cell expansion is associated with
598 reduced leukemia relapse after reduced intensity HCT. *Leukemia* 30 (2016) 456-63.
- 599 [25] A. Rolle, M. Meyer, S. Calderazzo, D. Jager, and F. Momburg, Distinct HLA-E Peptide
600 Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells. *Cell*
601 *Rep* 24 (2018) 1967-1976 e4.
- 602 [26] J. Nattermann, H.D. Nischalke, V. Hofmeister, B. Kupfer, G. Ahlenstiel, G. Feldmann,
603 J. Rockstroh, E.H. Weiss, T. Sauerbruch, and U. Spengler, HIV-1 infection leads to
604 increased HLA-E expression resulting in impaired function of natural killer cells.
605 *Antivir Ther* 10 (2005) 95-107.
- 606 [27] R. Thomas, H.Z. Low, K. Kniesch, R. Jacobs, R.E. Schmidt, and T. Witte, NKG2C
607 deletion is a risk factor of HIV infection. *AIDS Res Hum Retroviruses* 28 (2012) 844-
608 51.

- 609 [28] R. Zhang, J. Xu, K. Hong, L. Yuan, H. Peng, H. Tang, P. Ma, Y. Zhang, H. Xing, Y.
610 Ruan, and Y. Shao, Increased NKG2A found in cytotoxic natural killer subset in
611 HIV-1 patients with advanced clinical status. AIDS 21 Suppl 8 (2007) S9-17.
- 612 [29] D. Mele, B. Oliviero, S. Mantovani, S. Ludovisi, A. Lombardi, F. Genco, R. Gulminetti,
613 S. Novati, M.U. Mondelli, and S. Varchetta, Adaptive Natural Killer Cell Functional
614 Recovery in Hepatitis C Virus Cured Patients. Hepatology 73 (2021) 79-90.
- 615 [30] H. Vietzen, A. Zoufaly, M. Traugott, J. Aberle, S.W. Aberle, and E. Puchhammer-
616 Stockl, Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants
617 are risk factors for severe COVID-19. Genet Med 23 (2021) 963-967.
- 618 [31] C. Covian, A. Fernandez-Fierro, A. Retamal-Diaz, F.E. Diaz, A.E. Vasquez, M.K. Lay,
619 C.A. Riedel, P.A. Gonzalez, S.M. Bueno, and A.M. Kalergis, BCG-Induced Cross-
620 Protection and Development of Trained Immunity: Implication for Vaccine Design.
621 Front Immunol 10 (2019) 2806.
- 622 [32] G.T. Hart, T.M. Tran, J. Theorell, H. Schlums, G. Arora, S. Rajagopalan, A.D.J.
623 Sangala, K.J. Welsh, B. Traore, S.K. Pierce, P.D. Crompton, Y.T. Bryceson, and E.O.
624 Long, Adaptive NK cells in people exposed to Plasmodium falciparum correlate with
625 protection from malaria. J Exp Med 216 (2019) 1280-1290.
- 626 [33] J. Kleinnijenhuis, J. Quintin, F. Preijers, L.A. Joosten, C. Jacobs, R.J. Xavier, J.W. van
627 der Meer, R. van Crevel, and M.G. Netea, BCG-induced trained immunity in NK
628 cells: Role for non-specific protection to infection. Clin Immunol 155 (2014) 213-9.
- 629 [34] S.R. Jaiswal, J. Arunachalam, A. Bhardwaj, A. Saifullah, R. Lakhchaura, M. Soni, G.
630 Bhagawati, and S. Chakrabarti, Impact of adaptive natural killer cells, KLRC2
631 genotype and cytomegalovirus reactivation on late mortality in patients with severe
632 COVID-19 lung disease. Clin Transl Immunology 11 (2022) e1359.
- 633 [35] G. Esteso, N. Aguiló, E. Julian, O. Ashiru, M.M. Ho, C. Martin, and M. Vales-Gomez,
634 Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With
635 Heat-Killed BCG. Front Immunol 12 (2021) 622995.
- 636 [36] P. Riese, S. Trittel, R.D. Pathirana, F. Klawonn, R.J. Cox, and C.A. Guzman,
637 Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK
638 Cells. Vaccines (Basel) 8 (2020).
- 639 [37] R. Kamal, V. Pathak, A. Kumari, M. Natrajan, K. Katoch, and H.K. Kar, Addition of
640 Mycobacterium indicus pranii vaccine as an immunotherapeutic to standard
641 chemotherapy in borderline leprosy: a double-blind study to assess clinical
642 improvement (preliminary report). Br J Dermatol 176 (2017) 1388-1389.
- 643 [38] A. Gupta, F.J. Ahmad, F. Ahmad, U.D. Gupta, M. Natarajan, V. Katoch, and S. Bhaskar,
644 Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to
645 chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS
646 One 7 (2012) e39215.
- 647 [39] M. Subramaniam, L.L. In, A. Kumar, N. Ahmed, and N.H. Nagoor, Cytotoxic and
648 apoptotic effects of heat killed Mycobacterium indicus pranii (MIP) on various human
649 cancer cell lines. Sci Rep 6 (2016) 19833.
- 650 [40] D. Bortolotti, V. Gentili, S. Rizzo, A. Rotola, and R. Rizzo, SARS-CoV-2 Spike 1
651 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
652 Cells 9 (2020).
- 653 [41] T.D. Holmes, R.V. Pandey, E.Y. Helm, H. Schlums, H. Han, T.M. Campbell, T.T.
654 Drashansky, S. Chiang, C.Y. Wu, C. Tao, M. Shoukier, E. Tolosa, S. Von
655 Hardenberg, M. Sun, C. Kleemann, R.A. Marsh, C.M. Lau, Y. Lin, J.C. Sun, R.
656 Mansson, F. Cichocki, D. Avram, and Y.T. Bryceson, The transcription factor Bcl11b
657 promotes both canonical and adaptive NK cell differentiation. Sci Immunol 6 (2021).

- 658 [42] F. Cichocki, C.Y. Wu, B. Zhang, M. Felices, B. Tesi, K. Tuininga, P. Dougherty, E.
659 Taras, P. Hinderlie, B.R. Blazar, Y.T. Bryceson, and J.S. Miller, ARID5B regulates
660 metabolic programming in human adaptive NK cells. *J Exp Med* 215 (2018) 2379-
661 2395.
- 662 [43] I. Hwang, T. Zhang, J.M. Scott, A.R. Kim, T. Lee, T. Kakarla, A. Kim, J.B. Sunwoo,
663 and S. Kim, Identification of human NK cells that are deficient for signaling adaptor
664 FcRgamma and specialized for antibody-dependent immune functions. *Int Immunol*
665 24 (2012) 793-802.
- 666 [44] W. Liu, J.M. Scott, E. Langguth, H. Chang, P.H. Park, and S. Kim, FcRgamma Gene
667 Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive
668 Human NK Cells. *iScience* 23 (2020) 101709.
- 669 [45] X. Chen, C.A. Rostad, L.J. Anderson, H.Y. Sun, S.A. Lapp, K. Stephens, L. Hussaini, T.
670 Gibson, N. Roush, and E.J. Anderson, The development and kinetics of functional
671 antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike
672 protein. *Virology* 559 (2021) 1-9.
- 673 [46] R.K. Pandey, A. Sodhi, S.K. Biswas, Y. Dahiya, and M.K. Dhillon, *Mycobacterium*
674 *indicis pranii* mediates macrophage activation through TLR2 and NOD2 in a MyD88
675 dependent manner. *Vaccine* 30 (2012) 5748-54.
- 676 [47] P. Kumar, V. John, S. Marathe, G. Das, and S. Bhaskar, *Mycobacterium indicus pranii*
677 induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a
678 TLR-dependent manner. *J Leukoc Biol* 97 (2015) 511-20.
- 679 [48] S. Das, B.P. Chowdhury, A. Goswami, S. Parveen, J. Jawed, N. Pal, and S. Majumdar,
680 *Mycobacterium indicus pranii* (MIP) mediated host protective intracellular
681 mechanisms against tuberculosis infection: Involvement of TLR-4 mediated
682 signaling. *Tuberculosis (Edinb)* 101 (2016) 201-209.

683

684

685 LEGEND OF FIGURES

686 **Figure 1: Impact of Mw vaccination on COVID-19 compared to a control group:** Points
687 and connecting line plot show the infection trend in Mw group (n=50) and the Control group
688 (n=50). The x- axis shows the time in weeks and y- axis shows the Cumulative Incidence (CI)
689 in %. Red and black shaded circles represent Mw group and Control group respectively.

690 **Figure 2: Impact of Mw on both Adaptive NK (ANK) cells and inhibitory NK (iNK)**
691 **cells:**

692 A) Scatter dot with bar plot showing the expression of NKG2C⁺ ANK cells (Mw group -
693 n=30 and control group- n=15) and B) NKG2A⁺ iNK cells (Mw group-n=30 and control
694 group- n=15) with and without of Mw vaccine at baseline and day 60. C) Scatter dot with bar
695 plot showing kinetics of NKG2C⁺ ANK cells, and D) NKG2A⁺ iNK cells expression in Mw
696 group (n=30) at Baseline, day 30, day 60 and day 100. E) log2FC expression of NKG2C⁺ and
697 NKG2A⁺ in both Mw group (n=30) and Control group (n=15) at day 60 after normalization
698 with baseline. Red upside and downside shaded triangles represent NKG2C⁺ ANK and
699 NKG2A⁺ iNK respectively for Mw group. Black upside and downside shaded triangles
700 represent NKG2C⁺ ANK and NKG2A⁺ iNK respectively for Control group. ****- p <
701 0.0001, **- p <0.01, ***- p <0.001 and ns= p value not significant.

702 **Figure 3: Impact of Mw on upregulation of NKG2C⁺ ANK cells with respect to NKG2C**
703 **expression at baseline:** Scatter dot with bar plot showing the kinetics of A) NKG2C⁺ ANK
704 cells (n=15) and C) NKG2A⁺ iNK (n=15) cells expression in Mw group at baseline, day 30
705 and 60 in respect to <15% NKG2C at baseline. B) NKG2C⁺ ANK (n=15) cells and D)
706 NKG2A⁺ iNK (n=15) cells expression in Mw group at baseline, day 30 and 60 in respect to
707 >15% NKG2C at baseline. Log2FC expression of E) NKG2C⁺ ANK and F) NKG2A⁺ iNK
708 cells at day 60 after normalization with baseline value in Mw group (>/<15 %, n=15) and
709 control group. Red upside and downside shaded triangles represent NKG2C⁺ ANK and

710 NKG2A⁺ iNK respectively for Mw group. Black upside and downside shaded triangles
711 represent NKG2C⁺ ANK and NKG2A⁺ iNK respectively for Control group. ***- p <
712 0.0001, **- p < 0.01, *- p < 0.05 and ns= p value not significant.

713 **Figure 4: Mw showed sustained effect on NKG2C/NKG2A ratios until 100 days and**
714 **Impact of Mw intracellular Cytokine (IFN-γ) release:** Scatter dot with bar plot showing
715 A) NKG2C/NKG2A ratio of Control group (n=15) and Mw group (n=30) at baseline and day
716 60. B) Kinetics of NKG2C/NKG2A ratio at baseline, day 30, 60 and 100 in Mw group. C) &
717 D) Kinetics of NKG2C/NKG2A ratio at baseline and day 60 on the basis of >/< 15 %
718 NKG2C at baseline in Mw group and control group respectively. E) intracellular IFN-γ
719 release in both control (n=5) and Mw (n=5) group at baseline and day 60. Red and black
720 shaded circles represent Mw group and Control group respectively. ***- p < 0.0001, ***- p
721 < 0.001, *- p < 0.05 and ns= p value not significant.

722 **Figure 5: Relationship between NKG2C⁺ANK cells and COVID-19:** Scatter dot with bar
723 plot showing expression of NKG2C⁺ ANK cells at baseline in the overall cohort (no
724 infection, n=64 & infection, n=16), Control group (no infection, n=20 & infection, n=10) and
725 Mw group (no infection, n=44 & infection, n=6) with respect to SARS-CoV-2 infection.
726 Black and red upside shaded triangles represent NKG2C⁺ ANK for Control group and Mw
727 group respectively and unshaded upside triangles represent NKG2C⁺ ANK of both groups
728 combined. ***- p < 0.001, **- p < 0.01 and * - P < 0.05.

729 **Figure 6: Impact of the Second dose of Mw on Adaptive and Inhibitory NK cells:** Scatter
730 dot with bar plot showing expression of A) NKG2C⁺ ANK (day 60, single dose; n=17, double
731 dose; n=12 and day 100, single dose; n=17, double dose; n=12), B) NKG2A⁺ iNK cells (day
732 60, single dose; n=12, double dose; n=12 and day 100, single dose; n=17, double dose; n=12)
733 and C) NKG2C/NKG2A (day 60, single dose; n=17, double dose; n=12 and day 100, single
734 dose; n=17, double dose; n=12) ratio with respect to single and double dose of Mw vaccine at

735 day 60 and 100. Red upside and downside shaded triangles represent NKG2C⁺ ANK and
736 NKG2A⁺ iNK respectively for Mw group. Red shaded circle represents Mw group.
737 ****- p < 0.0001, **- p < 0.01, *- p < 0.05 and ns= p value not significant.

738 **Figure 7: Differential gene expression and network analysis in Mw and Control group:**

739 A) Volcano plot showing genes differentially expressed in Mw as compared to control group.
740 Genes with a p-value <0.05 and log2 Fold Change $\geq 0.5 \leq -0.5$ were considered significant.
741 Selected genes are highlighted (Red: Upregulated in Mw group, Blue: Upregulated in Control
742 group). B) Heatmap of RNA-seq expression data showing selected DEGs related to this
743 study. Hierarchical cluster analysis were performed between all samples of Mw and Control
744 group. Gene expression is shown in normalized log2 counts per million. C) Boxplots showing
745 expression levels of 19 selected genes in Mw (green) as compared to control group (orange).
746 Relative gene expression is shown in normalized log2 counts per million (log2CPM) for I)
747 ANK pathway in the top panel, II) ADCC pathway in the middle panel. (*p-value < 0.05,
748 **p-value < 0.01, ***p-value < 0.001, ****p-value<0.0001). D) GO network analysis of the
749 top 5 enriched GO terms in the differentially expressed genes for Adaptive NK cell and
750 Antibody-dependent Cellular Cytotoxicity (Fisher's exact test using enrichGO function in R
751 package clusterProfiler, multiple test correction by Benjamini- Hochberg method, adj. p-
752 value <0.05).

753 **Figure 8:** The suggested mechanistic pathway of the impact of Mw on ANK cells and
754 protection against COVID-19.

755

756

757

758

759

	Control group (N=50)	Mw group (N=50)	p-value
Age at vaccination, Median (Range), Years	28 (21-55)	28 (22-56)	0.11
<45	45	42	
>45	5	8	
Gender			0.3
Male	34	28	
Female	16	22	
SARS-CoV-2 Infection	17	3	0.0012
Mild	11	3	0.02
Moderate	6	0	0.01
Severe	0	0	1.0
Incidence rate/10000 person days	24.05	3.57	
Time to Infection, Median (Range), Mean, Days	56 (18-135) 66.4 ± 39.1	156 (151-159) 155.3 ± 4.0	<0.0001

760 **Table 1: Characteristics and Outcomes**

761

762 **Table 2: Incidence Rate Ratio of SARS-CoV-2 infections and Mw efficacy.**

Parameter	Estimate	p-value	95% CI
Incidence Rate Ratio (IRR)	0.15	0.0004	0.04 to 0.5
Attack rate in Mw control (ARU)	0.34		
Attack rate in Mw treated (ARV)	0.06		
Mw efficacy (%)	82.35%		50 to 96 %
Absolute Risk Reduction (ARR)	0.28		0.13 to 0.43
Number Needed to Treat (NNT)	3.6		2.3 to 7.5

763

764









Figure 2**(A)****(B)****(C)****(D)****(E)**







Figure 3**(A)****(B)****(E)****(C)****(D)****(F)**






Figure 4**(A)****(B)****(C)****(D)****(E)**

Figure 5












Figure 6**(A)****(B)****(C)**






Low NKG2C

High NKG2C

Low NKG2C

High NKG2C


NKG2C⁺ ANK cells



Monocyte

NKG2A⁺ iNK cells


NKG2A⁺ iNK cells



Cytokine mediated cytotoxicity

Viral destruction

ADCC (Antibody dependent cell cytotoxicity)



Target cell